NCT07038746View on ClinicalTrials.gov

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions

HypersensitivityAnaphylaxis

Interventions

DRUG

Inhaled Epinephrine

"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."

Trial Locations (1)

V7C 5L9

RECRUITING

Kokua Pharma Inc., Richmond

All Listed Sponsors

lead

Dr. George Luciuk

OTHER

NCT07038746 - Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges | Biotech Hunter | Biotech Hunter